Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Economic impact of diagnostic testing
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Kidney transplantation in highly sensitized patients

Economic impact of diagnostic testing

1 evidence topic · 1 source

French selection pathway: cost implications of diluted-serum HLA testing

“This recommendation increases significantly the cost of HLA testing” (opens the source at this quote in a new tab)